<DOC>
	<DOCNO>NCT02348359</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy X-82 treatment vision loss due wet AMD .</brief_summary>
	<brief_title>X-82 Treat Age-related Macular Degeneration</brief_title>
	<detailed_description>Subjects randomize 1:1:1:1 ratio follow dose group : - X-82 50 mg plus ivt anti-VEGF prn - X-82 100 mg plus ivt anti-VEGF prn - X-82 200 mg plus ivt anti-VEGF prn - Placebo plus ivt anti-VEGF prn Subjects treat total 52 week one three dose X-82 placebo . Primary Efficacy Outcome : The primary efficacy outcome change visual acuity score Day -1 52 Weeks randomization . Safety Outcomes : Systemic ocular safety evaluate assess ECG , laboratory analysis , adverse event serious adverse event . Approximately 132 subject randomize one four arm ( 33 subject per dose group ) .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Retinal Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Participants mush wet AMD diagnose treat antiVEGF one eye least 6 month prior join study require least two prior injection intravitreal ( ivt ) antiVEGF interval great 6 week past two injection eye select study eye . Must demonstrate reduction macular fluid macular thickness study eye 14 day follow antiVEGF injection Screening Visit 1 Early Treatment Diabetic Retinopathy ( ETDRS ) Best Corrected Visual Acuity ( BCVA ) 25 letter ( 20/320 ) good eye Previous vitrectomy study eye within 30 day Screening Visit 1 Choroidal neovascularization ( CNV ) due cause AMD Proliferative diabetic retinopathy either eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Vascular Endothelial Growth Factor ( VEGF )</keyword>
	<keyword>Platelet Derived Growth Factor ( PDGF )</keyword>
	<keyword>AMD</keyword>
</DOC>